leadf
logo-loader
viewMaxCyte Inc
(
AIM:MXCTFRA:MYE0
)

MaxCyte offering exposure to 'explosive growth' in cell therapy and cellular engineering

Proactive Research analyst Emma Ulker gives her view on the work MaxCyte Inc's (LON:MXCT) doing in the area of cell and gene therapy.

MXCT has more than 80 licensed programmes including more than 45 licensed for clinical use.

They've announced seven clinical/commercial partnership deals with leading names in the field of cell and gene therapy.

Ulker adds that the field is experiencing a huge step up in investment - rising by more than 77% year-on-year in 2018. 

Click here to read Emma Ulker's latest research note on MaxCyte

Quick facts: MaxCyte Inc

Follow
AIM:MXCT

Price: 1000 GBX

Market Cap: £1.01 billion

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

Maxcyte revenues rise 21%, hailing three new strategic licences with cell...

Proactive Research analyst Emma Ulker discusses MaxCyte's (LON:MXCT) commercial momentum across its cell therapy business, which led to 21% year-on-year top-line growth to US $26.2mln in fiscal (FY) 2020.  Ulker says this included three new strategic licences with high profile cell therapy...

on 29/4/21

2 min read